BioCrossroads launches new competition to foster convergence of life sciences and technology
INDIANAPOLIS, July 11, 2018 – BioCrossroads today announces the Indiana Inject Tech Challenge – a digital health competition that seeks to catalyze the creation of new, disruptive solutions designed to improve patient outcomes. Winners will be announced at the 2018 Indiana Life Sciences Summit on October 10.
The impetus for the new competition is to acknowledge and build upon accelerating convergence between the local life sciences and technology ecosystems as well as to identify local entrepreneurs in the two industries.
Entries should be based on one of the four challenge statements:
Challenge Statement 1
Digital health and mobile medical solutions for measuring/monitoring/treating disease progression in chronic pain conditions, prediabetes/diabetes, and/or diabetic complications through novel endpoints.
Challenge Statement 2
Identify a portable and fungible (across electronic health record data systems) solution to engage healthcare providers, enabling and incentivizing referrals (using workflow management and compensation features) into clinical research. Projects aligned to diabetes, pain, and/or autoimmune diseases will be prioritized.
Challenge Statement 3
Innovative, total support system/model to enable clinical trial participation of diverse populations.
Challenge Statement 4
A solution to transform and merge “omics” data and clinical data through advanced analytics and machine-learning to enable a new level of data interoperability, accessibility, and security.
Entries are due by September 4 and may be submitted at www.biocrossroads.com/injecttech.
Eli Lilly and Company is the presenting sponsor of the Inject Tech Challenge. Additional sponsors include Roche Diagnostics, Taft Law, Kronos, Black Inc. IT, and Indiana University.
Also today, BioCrossroads announced its agenda for the 2018 Indiana Life Sciences Summit. The Summit kicks off on Tues. Oct. 9 with an expanded scientific session, the New Venture Competition Winner announcement, a poster session and the Cook Medical and Eli Lilly and Company Networking Reception.
The speaker line-up for Oct. 9 and 10 includes TED-like talks life sciences leaders from corporations and start-ups who will discuss the integration of technology into the life sciences, including Christi Shaw, president, Lilly Bio-Medicines and senior vice president, Eli Lilly and Company; Don Brown, chairman and CEO, LifeOmic; John Hamer, managing director, DCVCBio; and Ketan Paranjape, vice president of diagnostics information solutions, Roche Diagnostics.
The Scientific Session will focus on metabolic disease research and development and will be a full-day conference on Tues. Oct. 9.
The Summit will take place at the Downtown Indianapolis Marriott. Sponsors of the conference include Cook Medical, Eli Lilly and Company, Faegre Baker Daniels, and Roche Diagnostics.
More information and registration are available www.biocrossroads.com.
BioCrossroads (www.biocrossroads.com) is Indiana’s initiative to grow, advance and invest in the life sciences, a public-private collaboration that supports the region’s existing research and corporate strengths while encouraging new business development. BioCrossroads provides money and support to life sciences businesses, launches new life sciences enterprises (Indiana Biosciences Research Institute, Indiana Health Information Exchange, AgriNovus Indiana, BioCrossroadsLINX, OrthoWorx and Datalys Center), expands collaboration and partnerships among Indiana’s life science institutions, promotes science education and markets Indiana’s life sciences industry.